'Effectiveness of Penfluridol (long acting neuroleptic) as compared to second generation oral neuroleptics (olanzapine and risperidone) in psychotic disorder patients: an open label randomized controlled trial'

INTERVENTION: comparison of (adherence of) two daily oral antipsychotics (olanzapine and risperidone) to a weekly oral antipsychotic (penfluridol) CONDITION: Psychotic disorders, Medication adherence ; ; PRIMARY OUTCOME: time to all‐cause medication discontinuation SECONDARY OUTCOME: ‐ healthcare related costs ; ; ‐ quality of life ; ; ‐ reason for treatment discontinuation ; ; ‐ efficacy ; ; ‐ safety and tolerability ; ; ‐ drug attitude ; ; ‐ subjective well‐being ; ; ‐ insight ; INCLUSION CRITERIA: 1. age 18‐65 years 2. psychotic disorder, including schizophrenia, schizoaffective disorder, delusional disorder or psychosis not otherwise specified 3. treatment on an outpatient basis or inpatient treatment followed by outpatient care (expected duration of admission less than 6 weeks) 4. psychiatrist treating the patient decides that it is appropriate (based on clinical judgement, guidelines, history and symptoms of the patient) to prescribe either penfluridol, olanzapine or risperidone and that there are no decisive contra‐indications 5. patient is willing to use oral neuroleptic treatment, including penfluridol, olanzapine or risperidone 6. able to give informed consent